Non Animal Testing, Alternative Test Methods, In Vitro Toxicology, IIVS | 2019 September 13
0
archive,date,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-17.2,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive

September 2019

Promoting the Uptake of Alternatives to Animal Testing Through the Development of eLearning Tools

September 13, 2019
In order to further promote the implementation of Directive 2010/63/EU, the European Commission issued calls for a number of related projects last year. One of these projects is aimed at facilitating the uptake of non-animal alternatives by developing two e-learning modules. The contract for this project was awarded to a consortium consisting of SYRCLE, the Swiss 3R Competence Centre, lnstitute for ln Vitro Sciences, Pharma Launcher and Ecorys UK. This consortium will develop two modules, i.e., one eLearning module focused...

kDPRA: An in chemico Method to Characterize the Skin Sensitization Potency of Chemicals

September 13, 2019
While the skin sensitization hazard of substances can readily be identified using non-animal methods, the classification of potency into UN GHS sub-categories 1A and 1B remains challenging. The kinetic direct peptide reactivity assay (kDPRA) is a modification of the DPRA (OECD TG 442C) wherein the reaction kinetics of a test substance towards a synthetic cysteine-containing peptide is evaluated. For this purpose, several concentrations of the test substance are incubated with the synthetic peptide for several incubation times at 25°C. After...

US EPA Commits to Dramatically Reduce Animal Testing

September 13, 2019
The US EPA has committed to dramatically reducing animal testing with a commitment for total elimination by the year 2035. IIVS is proud to have played a part in the move to reduce animal testing, starting with the successful development, and acceptance, of the non-animal eye-irritation defined approach, which was developed by an industry and regulatory consortium led by IIVS' CEO Rodger D. Curren, Ph.D. IIVS looks forward to continuing its collaboration with stakeholders to help the agency achieve its goals. Read the...